![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » COPAXONE RESULTS IMPRESSIVE COMPARED TO OTHER MS TREATMENTS
COPAXONE RESULTS IMPRESSIVE COMPARED TO OTHER MS TREATMENTS
June 21, 2005
A four-year study using a prospectively structured clinical database to assess comparative efficacy and safety of multiple sclerosis therapies, demonstrated that patients with relapsing-remitting multiple sclerosis treated with Copaxone (glatiramer acetate injection) showed superior relapse rate reduction than those treated with beta interferon therapies.
According to data presented at the European Neurological Society Meeting in Vienna, Austria, Copaxone produced the largest reduction, relative to pre-treatment in annual relapse rates at two, three and four years after the initiation of treatment, when compared to three beta interferon therapies: beta 1a (Avonex), 22 microgram interferon 1a (Rebif 22) and interferon beta 1b (Betaferon). Additionally, the best treatment adherence and lowest drop-out rate sustained over four years after the initiation of treatment was seen with Copaxone compared to the beta interferons.
The study represents a follow-up analysis to a two-year, open-label, non-randomized study recently published in the European Journal of Neurology
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct